Citations

Clear

4847 citation(s) found for "Tu, Eric".

Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2
Bryce, Alan H. , Crawford, E. David , Beltran, Himisha , Petrylak, Daniel P. , Armstrong, Andrew J. , Boike, Thomas , Calais, Jérémie , Chapin, Brian F. , Cookson, Michael S. , Davis, John W. , Dorff, Tanya B. , Eggener, Scott E. , Feng, Felix Y. , Higano, Celestia S. , Poage, Wendy, Scher, Howard I. , Sieber, Paul , Srinivas, Sandy, Zhang, Tian , Koo, Phillip J. , Beltran, Himisha , Cooperberg, Matthew R , Antonarakis, Emmanuel S , Aparicio, Ana M , Calais, Jeremie , Morris, Michael J , Scher, Howard I , Bryce, Alan H , Armstrong, Andrew J , Agarwal, Neeraj , Hussain, Maha , Shore, Neal D. , Spratt, Daniel E. , Tagawa, Scott T. , Carducci, Michael A. , Gleave, Martin , Iagaru, Andrei H. , Morgans, Alicia K. , Morris, Michael J. , Murray, Katie S. , Rettig, Matthew B. , Sartor, Oliver , Small, Eric J. , Yu, Evan Y

Mayo Clinic

JU Open Plus | April 15, 2024 | Volume: 2 | Issue: 4 | Pages: No page available

10.1097/ju9.0000000000000138 | PMID 38774467 Get It

Background: Management strategies for metastatic castration-resistant prostate cancer (mCRPC) have rapidly shifted in recent years. As novel imaging and therapeutic approaches have made their way to the clinic, providers are encountering increasingly challenging clinical scenarios, with limited guidance from the current literature. Materials and Methods: The US Prostate Cancer Conference (USPCC) is a multidisciplinary meeting of prostate cancer experts intended to address the many challenges of prostate cancer management. At the first annual USPCC meeting, areas of controversy and consensus were identified during a 2-day meeting that included expert presentations, full-panel discussions, and postdiscussion responses to questions developed by the USPCC cochairs and session moderators. Results: This narrative review covers the USPCC expert discussion and perspectives relevant to mCRPC, including neuroendocrine/aggressive-variant prostate cancer (NEPC/AVPC). Areas of broad agreement identified among USPCC experts include the benefits of poly (ADP-ribose) polymerase (PARP) inhibitors for patients with BRCA1/2 mutations, the use of radioligand therapy in patients with prostate-specific membrane antigen (PSMA)–positive mCRPC, and the need for clinical trials that address real-world clinical questions, including the performance of novel therapies when compared with modern standard-of-care treatment. Ongoing areas of controversy and uncertainty included the appropriateness of PARP inhibitors in patients with non-BRCA1/2 mutations, the optimal definition of PSMA positivity, and systemic therapies for patients with NEPC/AVPC after progression on platinum-based therapies. Conclusions: The first annual USPCC meeting identified several areas of controversy in the management of mCRPC, highlighting the urgent need for clinical trials designed to facilitate treatment selection and sequencing in this heterogeneous disease state.
Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1
Crawford, E. David , Beltran, Himisha , Petrylak, Daniel P. , Armstrong, Andrew J. , Boike, Thomas , Calais, Jérémie , Chapin, Brian F. , Cookson, Michael S. , Davis, John W. , Dorff, Tanya B. , Eggener, Scott E. , Feng, Felix Y. , Higano, Celestia S. , Poage, Wendy, Scher, Howard I. , Sieber, Paul , Srinivas, Sandy, Zhang, Tian , Koo, Phillip J. , Antonarakis, Emmanuel S , Aparicio, Ana M , Calais, Jeremie , Scher, Howard I , Armstrong, Andrew J , Bryce, Alan H. , Hussain, Maha , Agarwal, Neeraj , Cooperberg, Matthew R , Shore, Neal D. , Spratt, Daniel E. , Tagawa, Scott T. , Carducci, Michael A. , Gleave, Martin , Iagaru, Andrei H. , Morgans, Alicia K. , Morris, Michael J. , Murray, Katie S. , Rettig, Matthew B. , Sartor, Oliver , Small, Eric J. , Yu, Evan Y

Mayo Clinic

JU Open Plus | April 15, 2024 | Volume: 2 | Issue: 4 | Pages: No page available

10.1097/ju9.0000000000000137 | PMID 38774466 Get It

Purpose: Castration-sensitive prostate cancer (CSPC) is a complex and heterogeneous condition encompassing a range of clinical presentations. As new approaches have expanded management options, clinicians are left with myriad questions and controversies regarding the optimal individualized management of CSPC. Materials and Methods: The US Prostate Cancer Conference (USPCC) multidisciplinary panel was assembled to address the challenges of prostate cancer management. The first annual USPCC meeting included experts in urology, medical oncology, radiation oncology, and nuclear medicine. USPCC co-chairs and session moderators identified key areas of controversy and uncertainty in prostate cancer management and organized the sessions with multidisciplinary presentations and discussion. Throughout the meeting, experts responded to questions prepared by chairs and moderators to identify areas of agreement and controversy. Results: The USPCC panel discussion and question responses for CSPC-related topics are presented. Key advances in CSPC management endorsed by USPCC experts included the development and clinical utilization of gene expression classifiers and artificial intelligence (AI) models for risk stratification and treatment selection in specific patient populations, the use of advanced imaging modalities in patients with clinically localized unfavorable intermediate or high-risk disease and those with biochemical recurrence, recommendations of doublet or triplet therapy for metastatic CSPC (mCSPC), and consideration of prostate and/or metastasis-directed radiation therapy in select patients with mCSPC. Conclusions: CSPC is a diverse disease with many therapeutic options and the potential for adverse outcomes associated with either undertreatment or overtreatment. Future studies are needed to validate and clinically integrate novel technologies, including genomics, AI, and advanced imaging, to optimize outcomes among patients with CSPC.
Postoperative C5 Palsy after Anterior or Posterior Decompression for Degenerative Cervical Myelopathy
Bak, Alex B. , Moghaddamjou, Ali, Ahn, Henry, Shaffrey, Christopher I. , Mummaneni, Praveen V. , Jacobs, W. Bradley , Riew, K. Daniel , Hilibrand, Alan S. , Kim, Kee D. , Fourney, Daryl R. , Santaguida, Carlo , Massicotte, Eric M. , Kopjar, Branko , Alvi, Mohammed Ali , Farhadi, H. Francis , Nassr, Ahmad , Arnold, Paul M. , Riew, Kiehyun Daniel , Kelly, Michael P. , Brodke, Darrel Scott , Vaccaro, Alexander R. , Wilson, Jason, Harrop, James Shields , Fehlings, Michael G.

Mayo Clinic

Spine | April 15, 2024 | Volume: 49 | Issue: 20 | Pages: 1410-1416

10.1097/brs.0000000000005007 | PMID 38616732 Get It

Study Design. Retrospective cohort study of prospectively accrued data. Objective. To evaluate a large, prospective, multicentre dataset of surgically treated degenerative cervical myelopathy (DCM) cases on the contemporary risk of C5 palsy with surgical approach. Summary of Background Data. The influence of surgical technique on postoperative C5 palsy after decompression for DCM is intensely debated. Comprehensive, covariate-adjusted analyses are needed using contemporary data. Methods. Patients with moderate to severe DCM were prospectively enrolled in the multicenter, randomized, Phase III CSM-Protect clinical trial and underwent either anterior or posterior decompression between Jan 31, 2012 and May 16, 2017. The primary outcome was the incidence of postoperative C5 palsy, defined as the onset of muscle weakness by at least one grade in manual muscle test at the C5 myotome with slight or absent sensory disruption after cervical surgery. Two comparative cohorts were made based on the anterior or posterior surgical approach. Multivariate hierarchical mixed-effects logistic regression was used to estimate odds ratios (OR) with 95% confidence intervals (CI) for C5 palsy. Results. A total of 283 patients were included, and 53.4% underwent posterior decompression. The total incidence of postoperative C5 palsy was 7.4% and was significantly higher in patients who underwent posterior decompression compared with anterior decompression (11.26% vs. 3.03%, P=0.008). After multivariable regression, the posterior approach was independently associated with greater than four times the likelihood of postoperative C5 palsy (P=0.017). Rates of C5 palsy recovery were comparable between the two surgical approaches. Conclusion. The odds of postoperative C5 palsy are significantly higher after posterior decompression compared to anterior decompression for DCM. This may influence surgical decision-making when there is equipoise in deciding between anterior and posterior treatment options for DCM. Level of Evidence. Therapeutic Level—II
How Artificial Intelligence Can Enhance the Diagnosis of Cardiac Amyloidosis: A Review of Recent Advances and Challenges
Kamel, Moaz, Abbas, Mohammed Tiseer , Kanaan, Christopher , Awad, Kamal A., Ali, Nima Baba , Scalia, Isabel G. , Farina, Juan M. , Pereyra, Milagros , Mahmoud, Ahmed , Steidley, D. Eric , Rosenthal, Julie , Arsanjani, Reza , Awad, Kamal , Kamel, Moaz A, Kanaan, Christopher N , Baba Ali, Nima, Mahmoud, Ahmed K , Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Scalia, Isabel G , Abbas, Mohammed Tiseer , Awad, Kamal

Mayo Clinic

Journal of Cardiovascular Development and Disease | April 15, 2024 | Volume: 11 | Issue: 4 | Pages: 118

10.3390/jcdd11040118 | PMID 38667736 Get It

Cardiac amyloidosis (CA) is an underdiagnosed form of infiltrative cardiomyopathy caused by abnormal amyloid fibrils deposited extracellularly in the myocardium and cardiac structures. There can be high variability in its clinical manifestations, and diagnosing CA requires expertise and often thorough evaluation; as such, the diagnosis of CA can be challenging and is often delayed. The application of artificial intelligence (AI) to different diagnostic modalities is rapidly expanding and transforming cardiovascular medicine. Advanced AI methods such as deep-learning convolutional neural networks (CNNs) may enhance the diagnostic process for CA by identifying patients at higher risk and potentially expediting the diagnosis of CA. In this review, we summarize the current state of AI applications to different diagnostic modalities used for the evaluation of CA, including their diagnostic and prognostic potential, and current challenges and limitations.
Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial
Babu, Suma , Nicholson, Katharine, Sampognaro, Paul J., Pant, Pravin, Spruill, Susan E. , Prudencio, Mercedes , Petrucelli, Leonard , Nix, Darrell, Landrette, Sean F., Nkrumah, Esther, Fandrick, Keith R. , Edwards, Joan, Prudencio, Mercedes , Rothstein, Jeffrey D. , Swenson, Andrea , Macklin, Eric A. , Paganoni, Sabrina , Gendron, Tania F. , Young, Peter R

Mayo Clinic

Brain | April 12, 2024 | Volume: 147 | Issue: 9 | Pages: 2998-3008

10.1093/brain/awae109 | PMID 38606777 Get It

Abstract Apilimod dimesylate is a first-in-class phosphoinositide kinase, FYVE-type zinc finger-containing (PIKfyve) inhibitor with a favourable clinical safety profile and has demonstrated activity in preclinical C9orf72 and TDP-43 amyotrophic lateral sclerosis (ALS) models. In this ALS clinical trial, the safety, tolerability, CNS penetrance and modulation of pharmacodynamic target engagement biomarkers were evaluated. This phase 2a, randomized, double-blind, placebo-controlled, biomarker-end-point clinical trial was conducted in four US centres (ClinicalTrials.gov NCT05163886). Participants with C9orf72 repeat expansions were randomly assigned (2:1) to receive twice-daily oral treatment with 125 mg apilimod dimesylate capsules or matching placebo for 12 weeks, followed by a 12-week open-label extension. Safety was measured as the occurrence of treatment-emergent or serious adverse events attributable to the study drug and tolerability at trial completion or treatment over 12 weeks. Changes from baseline in plasma and CSF and concentrations of apilimod dimesylate and its active metabolites and of pharmacodynamic biomarkers of PIKfyve inhibition [soluble glycoprotein nonmetastatic melanoma protein B (sGPNMB) upregulation] and disease-specific CNS target engagement [poly(GP)] were measured. Between 16 December 2021 and 7 July 2022, 15 eligible participants were enrolled. There were no drug-related serious adverse events reported in the trial. Fourteen (93%) participants completed the double-blind period with 99% dose compliance [n = 9 (90%) apilimod dimesylate; n = 5 (100%) placebo]. At Week 12, apilimod dimesylate was measurable in CSF at 1.63 ng/ml [standard deviation (SD): 0.937]. At Week 12, apilimod dimesylate increased plasma sGPNMB by >2.5-fold (P < 0.001), indicating PIKfyve inhibition, and lowered CSF poly(GP) protein levels by 73% (P < 0.001), indicating CNS tissue-level proof of mechanism. Apilimod dimesylate met prespecified key safety and biomarker end-points in this phase 2a trial and demonstrated CNS penetrance and pharmacodynamic target engagement. Apilimod dimesylate was observed to result in the greatest reduction in CSF poly(GP) levels observed to date in C9orf72 clinical trials.
Application of PET/MRI in Gynecologic Malignancies
Ebrahimi, Sheida , Lundström, Elin , Batasin, Summer, Hedlund, Elisabeth, Stålberg, Karin , Ehman, Eric C. , Iranpour, Negaur, Loubrie, Stéphane , Schlein, Alexandra , Rakow‐Penner, Rebecca , Rakow-Penner, Rebecca , Sheth, Vipul R.

Mayo Clinic

Cancers | April 12, 2024 | Volume: 16 | Issue: 8 | Pages: 1478

10.3390/cancers16081478 | PMID 38672560 Get It

The diagnosis, treatment, and management of gynecologic malignancies benefit from both positron emission tomography/computed tomography (PET/CT) and MRI. PET/CT provides important information on the local extent of disease as well as diffuse metastatic involvement. MRI offers soft tissue delineation and loco-regional disease involvement. The combination of these two technologies is key in diagnosis, treatment planning, and evaluating treatment response in gynecological malignancies. This review aims to assess the performance of PET/MRI in gynecologic cancer patients and outlines the technical challenges and clinical advantages of PET/MR systems when specifically applied to gynecologic malignancies.
Second Primary Breast Cancer in Young Breast Cancer Survivors
Rosenberg, Shoshana M. , Collins, Laura C. , Ruddy, Kathryn J. , Schapira, Lidia , Come, Steven E. , Brantley, Kristen D. , Tamimi, Rulla M. , Borges, Virginia F. , Warner, Ellen , Zheng, Yue , Kirkner, Gregory J. , Snow, Craig , Winer, Eric P. , Partridge, Ann H.

Mayo Clinic

JAMA Oncology | April 11, 2024 | Volume: 10 | Issue: 6 | Pages: 718

10.1001/jamaoncol.2024.0286 | PMID 38602683 Get It

Importance Among women diagnosed with primary breast cancer (BC) at or younger than age 40 years, prior data suggest that their risk of a second primary BC (SPBC) is higher than that of women who are older when they develop a first primary BC. Objective To estimate cumulative incidence and characterize risk factors of SPBC among young patients with BC. Design, Setting, and Participants Participants were enrolled in the Young Women’s Breast Cancer Study, a prospective study of 1297 women aged 40 years or younger who were diagnosed with stage 0 to III BC from August 2006 to June 2015. Demographic, genetic testing, treatment, and outcome data were collected by patient surveys and medical record review. A time-to-event analysis was used to account for competing risks when determining cumulative incidence of SPBC, and Fine-Gray subdistribution hazard models were used to evaluate associations between clinical factors and SPBC risk. Data were analyzed from January to May 2023. Main Outcomes and Measures The 5- and 10- year cumulative incidence of SPBC. Results In all, 685 women with stage 0 to III BC (mean [SD] age at primary BC diagnosis, 36 [4] years) who underwent unilateral mastectomy or lumpectomy as the primary surgery for BC were included in the analysis. Over a median (IQR) follow-up of 10.0 (7.4-12.1) years, 17 patients (2.5%) developed an SPBC; 2 of these patients had cancer in the ipsilateral breast after lumpectomy. The median (IQR) time from primary BC diagnosis to SPBC was 4.2 (3.3-5.6) years. Among 577 women who underwent genetic testing, the 10-year risk of SPBC was 2.2% for women who did not carry a pathogenic variant (12 of 544) and 8.9% for carriers of a pathogenic variant (3 of 33). In multivariate analyses, the risk of SPBC was higher among PV carriers vs noncarriers (subdistribution hazard ratio [sHR], 5.27; 95% CI, 1.43-19.43) and women with primary in situ BC vs invasive BC (sHR, 5.61; 95% CI, 1.52-20.70). Conclusions Findings of this cohort study suggest that young BC survivors without a germline pathogenic variant have a low risk of developing a SPBC in the first 10 years after diagnosis. Findings from germline genetic testing may inform treatment decision-making and follow-up care considerations in this population.
Ten Years of Pathology on Twitter (X): Landscape and Evolution of Pathology on Twitter From 2012 to 2023
Tian, Roland, Wang, Eric , Sivasubramaniam, Priyadharshini , Baskota, Swikrity Upadhyay , Sharma, Anurag , Cecchini, Matthew J.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | April 10, 2024 | Volume: 149 | Issue: 1 | Pages: 75-82

10.5858/arpa.2023-0447-oa | PMID 38599590 Get It

Context.— Social media is a powerful tool in pathology education and professional networking that connects pathologists and pathology trainees from around the world. Twitter (X) appears to be the most popular social media platform pathologists use to share pathology-related content and connect with other pathologists. Although there has been some published research on pathology-related activity on Twitter during short time frames, to date there has not been published research examining pathology-related Twitter activity in totality from its earliest days of activity to recently. Objective.— To comprehensively evaluate the use of pathology on Twitter (X) during the last 10 years. Design.— Pathology-related tweets were systematically scraped from Twitter from January 2012 to January 2023 using pathology hashtags as a surrogate measure for all pathology content on Twitter. COVID-related tweets were approximated by tweets containing the term “COVID.” Results.— There were 591 812 unique pathology-related tweets identified during the time period, with #pathology being the most common hashtag used and #PathTwitter becoming more popular since 2020. There has been positive annual growth of pathology Twitter, with peaks in use during major pathology conferences. During the initial phases of the COVID-19 pandemic, a sustained increase in pathology tweets was observed. Conclusions.— Pathology Twitter has grown during the last 10 years and has become increasingly popular for pathology education and networking. With the changing landscape of social media platforms, this study provides an understanding of how pathology medical education and professional networking uses of social media happen and evolve over time.
Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101
Batchelor, Tracy T. , Giri, Sharmila, Ruppert, Amy S. , Geyer, Susan M. , Smith, Scott E. , Mohile, Nimish, Swinnen, Lode J., Friedberg, Jonathan W. , Kahl, Brad S. , Bartlett, Nancy L. , Cheson, Bruce D. , Wagner‐Johnston, Nina D. , Nayak, Lakshmi , Leonard, John P. , Rubenstein, James L. , Hsi, Eric D , Wagner-Johnston, Nina , Bartlett, Nancy L , Kahl, Brad S , Hsi, Eric D.

Mayo Clinic

Blood Advances | April 10, 2024 | Volume: 8 | Issue: 12 | Pages: 3189-3199

10.1182/bloodadvances.2023011657 | PMID 38598710 Get It

Abstract Although it is evident that standard-dose whole-brain radiotherapy as consolidation is associated with significant neurotoxicity, the optimal consolidative strategy for primary central nervous system lymphoma (PCNSL) is not defined. We performed a randomized phase 2 clinical trial via the US Alliance cancer cooperative group to compare myeloablative consolidation supported by autologous stem cell transplantation with nonmyeloablative consolidation after induction therapy for PCNSL. To our knowledge, this is the first randomized trial to be initiated that eliminates whole-brain radiotherapy as a consolidative approach in newly diagnosed PCNSL. Patients aged 18 to 75 years were randomly assigned in a 1:1 manner to induction therapy (methotrexate, temozolomide, rituximab, and cytarabine) followed by consolidation with either thiotepa plus carmustine and autologous stem cell rescue vs induction followed by nonmyeloablative, infusional etoposide plus cytarabine. The primary end point was progression-free survival (PFS). A total of 113 patients were randomized, and 108 (54 in each arm) were evaluable. More patients in the nonmyeloablative arm experienced progressive disease or death during induction (28% vs 11%; P = .05). Thirty-six patients received autologous stem cell transplant, and 34 received nonmyeloablative consolidation. The estimated 2-year PFS was higher in the myeloablative vs nonmyeloablative arm (73% vs 51%; P = .02). However, a planned secondary analysis, landmarked at start of the consolidation, revealed that the estimated 2-year PFS in those who completed consolidation therapy was not significantly different between the arms (86% vs 71%; P = .21). Both consolidative strategies yielded encouraging efficacy and similar toxicity profiles. This trial was registered at www.clininicals.gov as #NCT01511562.
Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study
Crane, Genevieve M. , Geyer, Julia T. , Wang, Sa A. , Li, Ke David, Davis, Adam R. , Bosler, David , Bueso‐Ramos, Carlos E. , Bagg, Adam , Hasserjian, Robert P. , Hsi, Eric D , Thakral, Beenu , Wool, Geoffrey D. , Boiocchi, Leonardo , Arber, Daniel A. , George, Tracy I. , Orazi, Attilio , Hsi, Eric D. , Rogers, Heesun J.

Mayo Clinic

American Journal of Clinical Pathology | April 10, 2024 | Volume: 162 | Issue: 3 | Pages: 233-242

10.1093/ajcp/aqae033 | PMID 38597584 Get It

Abstract Objectives Myeloproliferative neoplasm, unclassifiable (MPN-U, revised to MPN, not otherwise specified in the fifth edition of the World Health Organization classification) is a heterogeneous category of primary marrow disorders with clinical, morphologic, and/or molecular features that preclude classification as a more specific MPN subtype due to stage at diagnosis, overlapping features between MPN subtypes, or the presence of coexisting disorders. Compared with other MPN subtypes, the contribution of the mutational landscape in MPN-U in conjunction with other clinical and morphologic biomarkers to prognosis has been less well investigated. Methods We performed a multicenter, retrospective study of MPN-U (94 cases) to better define the clinicopathologic features, genetic landscape, and clinical outcomes, including subgroups of early-stage, advanced-stage, and coexisting disorders. The Dynamic International Prognostic Scoring System (DIPSS) plus scoring system was applied to assess its relevance to MPN-U prognosis. Results Multivariate analysis demonstrated bone marrow blast count and DIPSS plus score as statistically significant in predicting overall survival. Univariate analysis identified additional potential poor prognostic markers, including abnormal karyotype and absence of JAK2 mutation. Secondary mutations were frequent in the subset analyzed by next-generation sequencing (26/37 cases, 70.3%) with a borderline association between high molecular risk mutations and overall survival. Conclusions This study, as one of the largest of MPN-U studies incorporating both clinicopathologic and molecular data, moves toward identification of biomarkers that better predict prognosis in this heterogeneous category.